Literature DB >> 6297930

Dopamine receptor profile of co-dergocrine (Hydergine) and its components.

R Markstein.   

Abstract

Co-dergocrine (Hydergine), an ergot preparation composed of four dihydrogenated peptide ergot alkaloids (dihydroergocornine, dihydroergocristine, dihydro-alpha-ergokryptine, dihydro-beta-ergokryptine, 3:3:2:1), has been reported to exert in vivo effects suggesting an interaction with dopaminergic systems. The present investigation provides evidence that, in the striatum of the rat, co-dergocrine and its components interact directly with D1- and D2-subtypes of dopamine receptors. In homogenates of rat striatum, co-dergocrine and three of its components (dihydroergocornine, dihydro-alpha-ergokryptine, dihydro-beta-ergokryptine) stimulate cyclic AMP formation (D1-receptor response) having similar EC50 values but different efficacies. The same compounds inhibit electrically evoked tritium overflow from rat striatal slices preincubated with [3H]choline (D2-receptor response) at about 50 times lower concentrations. Here again the compounds exhibit differential maximal effects. One component, dihydroergocristine, antagonises both receptor types. The effect of co-dergocrine in functional responses mediated by both D1- and D2-receptors seems to reflect the summation of the contribution of its components.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6297930     DOI: 10.1016/0014-2999(82)90312-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

Review 1.  Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia.

Authors:  C D Nicholson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  Proceedings of the British Pharmacological Society. University of Dundee, 11th-14th September, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

Review 3.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

4.  Coenzyme Q, peroxidation and cytochrome oxidase features after parkinson's-like disease by MPTP toxicity in intra-synaptic and non-synaptic mitochondria from Macaca fascicularis cerebral cortex and hippocampus: action of dihydroergocriptine.

Authors:  M Battino; G P Littarru; A Gorini; R F Villa
Journal:  Neurochem Res       Date:  1996-12       Impact factor: 3.996

5.  Parkinson-like disease by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) toxicity in Macaca fascicularis: synaptosomal metabolism and action of dihydroergocriptine.

Authors:  R F Villa; R Arnaboldi; B Ghigini; A Gorini
Journal:  Neurochem Res       Date:  1994-03       Impact factor: 3.996

6.  Mitochondrial factors involved in Parkinson's disease by MPTP toxicity in Macaca fascicularis and drug effect.

Authors:  R F Villa; R Arnaboldi; B Ghigini; A Gorini
Journal:  Neurochem Res       Date:  1992-11       Impact factor: 3.996

7.  Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  In vitro effect of the racemic mixture and the (-)enantiomer of N-n-propyl-3-(3-hydroxyphenyl)-piperidine (3-PPP) on postsynaptic dopamine receptors and on a presynaptic dopamine autoreceptor.

Authors:  R Markstein; D Lahaye
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.